Seres Therapeutics (MCRB) announced that new post hoc data from its SER-155 Phase 1b trial will be featured in an oral presentation at IDWeek 2025, taking place October 19-22 in Atlanta, Georgia. The presentation will include new data describing differences between the SER-155 and placebo groups in the bacterial and fungal organisms causing BSIs, including BSI event clinical outcomes, antibacterial prophylaxis use, and patterns of antimicrobial resistance among the bacterial BSI organisms.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCRB: